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However, some studies have suggested a “smoker’s paradox,” meaning neutral or favorable outcomes in smokers who
have developed CAD, especially myocardial infarction (MI).
OBJECTIVES The study aimed to examine the association of smoking status with clinical outcomes in the randomized
controlled SYNTAX (SYNergy Between PCI With TAXUS and Cardiac Surgery) trial at 5-year follow-up.
METHODS Detailed smoking history was collected at baseline, 6-month, 1-year, 3-year, and 5-year follow-up. The
composite endpoints included death/MI/stroke (primary endpoint) plus major adverse cardiac and cerebrovascular events
(MACCE) (combination of death/MI/stroke and target lesion revascularization) according to patient smoking status. The
comparison of 5-year clinical outcomes between the groups according to smoking status was performed with Cox
regression using smoking status at baseline or smoking as a time-dependent covariate.
RESULTS A sizeable proportion (n ¼ 322, 17.9%) of patients had changing smoking status during 5-year follow-up. One
in 5 patients with complex CAD was smoking at baseline. However, 60% stopped after revascularization while others
continued to smoke. Smokers had worse clinical outcomes due to a higher incidence of recurrent MI in both revascu-
larization arms. Smoking was an independent predictor of the composite endpoint of death/MI/stroke (hazard ratio [HR]:
1.8; 95% conﬁdence interval [CI]: 1.3 to 2.5; p ¼ 0.001) and MACCE (HR: 1.4; 95% CI: 1.1 to 1.7; p ¼ 0.02).
CONCLUSIONS Smoking is associated with poor clinical outcomes after revascularization in patients with complex CAD.
This places further emphasis on efforts at smoking cessation to improve revascularization beneﬁts. (SYNTAX Study:
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ABBR EV I A T I ON S
AND ACRONYMS
CABG = coronary artery
bypass grafting
CI = conﬁdence interval
HR = hazard ratio
MACCE = major adverse
cardiac and cerebrovascular
event(s)
MI = myocardial infarction
PCI = percutaneous
coronary intervention
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1108C igarette smoking is a globally well-recognized risk factor for coronaryartery disease (CAD) (1–5). Smokers
with ischemic heart disease also have higher
incidence of death and other adverse events
(5,6). However, some studies have suggested
existence of a “smoker’s paradox,” meaning
the outcomes in smokers who have devel-
oped CAD, especially myocardial infarc-
tion (MI), may be neutral or better than
nonsmokers (7–9). It is likely that the
observed paradox is largely due to differ-ences in the baseline characteristics of smokers and
nonsmokers in these studies (7,8), or there may be
an interaction between smoking and efﬁcacy of anti-
platelet drugs (10,11). However, such reports can
have a negative public health impact. Indeed, more
than one-third of smokers believe that the dangers
of smoking are greatly exaggerated (12). It is, there-
fore, important to study the effect of smoking on out-
comes in patients with established CAD to better
understand the effects of smoking on outcomes.SEE PAGE 1116The deleterious effects of smoking after coronary
artery bypass grafting (CABG) and percutaneous cor-
onary intervention (PCI) have been shown previously
(13–17), although other studies suggested a smoker’s
paradox in this context as well (18,19). However, the
smoking status in most of these studies is usually
taken at baseline and not collected again at regular
intervals. Conversely, smokers who learn they have
established CAD may stop smoking permanently or
intermittently. Therefore, assessing the impact of
smoking status at baseline for long-term outcomes
may be unreliable. Additionally, most studies were
performed in the era of PCI without stents or with
bare-metal stents, providing little insight into the
impact of smoking in patients undergoing revascu-
larization with drug-eluting stents. Furthermore, the
effect of smoking on clinical events in patients with
complex CAD undergoing PCI or CABG remains
undeﬁned.
This study aimed to examine the smoking status in
patients with complex coronary artery disease under-
going PCI or CABG and its prognostic signiﬁcance in
the SYNTAX (SYNergy Between PCI With TAXUS and
Cardiac Surgery) trial at the ﬁnal 5-year follow-up.
METHODS
The SYNTAX trial (NCT00114972) was a prospective,
multicenter, randomized trial that compared PCI with
CABG for patients with complex CAD (left mainstem and/or 3-vessel disease) (20). Eligible patients
(n ¼ 1,800) were randomized on a 1:1 ratio to CABG
(n ¼ 897) or PCI (n ¼ 903) with TAXUS Express
paclitaxel-eluting stents (Boston Scientiﬁc Corpora-
tion, Natick, Massachusetts) and followed for 5 years.
The study complied with the Declaration of Helsinki
and was approved by the ethical review board of the
institution involved.
Smoking status was checked for all patients at
baseline, 6 months, and 1, 3, and 5 years. The study
endpoint was the impact of smoking on a composite
endpoint (death/MI/stroke) at 5-year follow-up. We
also evaluated impact of smoking on other clinical
endpoints including major cardiac and cerebrovascu-
lar events (MACCE) (combination of death/MI/stroke/
target vessel revascularization). Deﬁnitions of various
clinical endpoints (e.g., MI, stroke) in the SYNTAX
trial have been previously reported (20). All events
were adjudicated by an independent clinical event
committee comprising interventional cardiologists,
cardiac surgeons, and a neurologist (21).
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD and categorical variables are
shown as counts and percentages of the total. Com-
parison of 5-year clinical outcomes between the
groups according to the smoking status was per-
formed with Cox regression using smoking status at
baseline or smoking as a time-dependent covariate.
Hazard ratios (HR) with 95% conﬁdence intervals (CI)
are shown. Chi-square test was used to assess inter-
action p values for treatment arms. A probability
value of <0.05 was considered statistically signiﬁ-
cant. All analyses were performed using SPSS version
21.0 (IBM Corp., Armonk, New York) and STATA
version 12.0 (Stata Corp. LP, College Station, Texas).
RESULTS
In the randomized SYNTAX trial (n ¼ 1,800), infor-
mation on smoking status was available for 1,793
(99.6%) patients. The proportion of patients smoking
at different time points is shown in Figure 1. While
20.2% patients with extensive CAD were still smoking
at baseline, a signiﬁcant number stopped smoking
after revascularization (8.6% were smokers at 6
months and 8.7% at 1 year). However, after 1 year,
there was a modest increase in number of smokers,
especially in the CABG arm (10.8% were smokers in
the CABG arm vs. 8.7% in the PCI group at 5-year
follow-up). Overall, 321 (17.9%) patients had a
change in smoking status during follow-up. While
nonsmokers remained nonsmokers, current and ex-
smokers had considerable change in their smoking
status across the 5 years (Table 1).
FIGURE 1 Smoking Status of Patients in the SYNTAX Trial at 5-Year Follow-Up
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The smoking status of patients stratiﬁed into smokers, ex-smokers, and nonsmokers is dis-
played for overall SYNTAX (SYNergy Between PCI With TAXUS and Cardiac Surgery) trial
patients as well as coronary artery bypass grafting (CABG) and percutaneous coronary
intervention (PCI) arms. While the proportion of nonsmokers remained constant, there were
changes inproportion of smokers andex-smokers, as nearly half of smokers stopped smoking
after the index procedure but some relapsed during follow-up. Ex-smoker was deﬁned as a
smoker quitting more than 1 month before the index procedure or follow-up time point.
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smoking status—stratiﬁed as smokers, ex-smokers,
and nonsmokers (Online Table 1A) and smoking or
nonsmoking at baseline (Online Table 1B)—revealed
that smokers were younger and predominantly
male and had extensive CAD despite lower preva-
lence of other cardiovascular risk factors including
diabetes mellitus, hypertension, or dyslipidemia.
Conversely, smokers had more prevalent chronic
obstructive pulmonary disease (COPD), peripheral
vascular disease (PVD), and poor left ventricular
ejection fraction.
EFFECT OF SMOKING ON CLINICAL OUTCOMES.
Baseline smoking status appeared to have no impact
on death/MI/stroke and MACCE at 5-year follow-up
(Figure 2A). Analyzing the data for those smoking or
not smoking at baseline also yielded similar results
(Figure 2B). However, considering that the smoking
status changed during 5-year follow-up, the analysis
with smoking as a time-dependent variable revealed
that smoking was associated with increased risk of
death/MI/stroke (HR: 1.38; 95% CI: 1.02 to 1.86;
p ¼ 0.035) and MACCE (HR: 1.28; 95% CI: 1.01 to 1.61;
p ¼ 0.041) at 5-year follow-up (Figure 2C). In total,
1,374 patients never smoked and 98 patients always
smoked during 5-year follow-up. The patients who
always smoked had signiﬁcantly higher risk of MI and
stent thrombosis/graft occlusion, but not all-cause
revascularization, compared with those who never
smoked (Online Figure 1).
The baseline smoking status (current smoker
vs. ex-smoker vs. nonsmoker) was associated with
higher risk of MI during 5-year follow-up (Online
Figure 2A). Analyzing the data for those smoking or
not smoking at baseline yielded similar results
(Online Figure 2B). The predominant effect of smok-
ing as a time-dependent covariate was on subsequent
MI (unadjusted HR: 1.86; 95% CI: 1.21 to 2.86;
p ¼ 0.005; adjusted HR: 2.08; 95% CI: 1.30 to 3.32;
p ¼ 0.002) (Figure 3, Table 2), whereas no statistically
signiﬁcant effect was observed on mortality or repeat
revascularization at 5-year follow-up (Figure 3). The
interaction p values for these outcomes between
CABG and PCI arms were not signiﬁcant, suggesting
smoking was associated with poor outcomes inde-
pendent of revascularization strategy (Figure 3).
On multivariable Cox regression analysis using
smoking status as a time-dependent covariate,
smoking was an independent predictor of death/MI/
stroke as well as MACCE (Table 3). Subgroup analysis
showed that smoking was an independent predictor
of poor outcomes in CABG patients (HR: 1.52; 95% CI:
1.02 to 2.25; p ¼ 0.038) as well as the PCI arm(HR: 1.26; 95% CI: 0.90 to 1.75; p ¼ 0.177). After
adjusting for other independent predictors, baseline
smoking status also was associated with poor out-
comes (Central Illustration).
TABLE 1 Smoking Pattern in SYNTAX Patients During 5-Year Follow-Up*
Baseline 6 Months 12 Months 36 Months 60 Months n (%)
Smoking status unchanged during follow-up 1,472 (82.1)
D D D D D 98 (5.5)
     1,374 (76.6)
Smoking status changing during follow-up 321 (17.9)
Smoking at baseline but changing status during follow-up 265 (14.8)
D D D D  14 (0.78)
D D D  D 4 (0.22)
D D D   17 (0.95)
D D  D D 2 (0.11)
D D   D 2 (0.11)
D D    13 (0.73)
D  D D D 12 (0.67)
D  D  D 2 (0.11)
D  D   3 (0.17)
D   D D 16 (0.89)
D   D  4 (0.22)
D    D 11 (0.61)
D     122 (6.80)
D  3 3 3 6 (0.33)
D D  3 3 8 (0.45)
D   3 3 8 (0.45)
D D D  3 1 (0.06)
D D  D 3 1 (0.06)
D D   3 3 (0.17)
D  D D 3 2 (0.11)
D  D  3 1 (0.06)
D   D 3 5 (0.28)
D    3 8 (0.45)
Nonsmoking at baseline but changing status during follow-up 56 (3.1)
 D D D D 6 (0.33)
 D D D  2 (0.11)
 D D  D 1 (0.06)
 D    1 (0.06)
  D D D 3 (0.17)
  D  D 1 (0.06)
  D   5 (0.28)
   D D 16 (0.89)
   D  4 (0.22)
    D 10 (0.56)
 D D D 3 1 (0.06)
  D D 3 1 (0.06)
   D 3 4 (0.22)
 D 3 3 3 1 (0.06)
Values are n (%). *þ ¼ smoking;  ¼ nonsmoking; 3 ¼ the subjects who died or were lost during follow-up.
SYNTAX ¼ SYNergy Between PCI With TAXUS and Cardiac Surgery.
Zhang et al. J A C C V O L . 6 5 , N O . 1 1 , 2 0 1 5
SYNTAX, Smoking, and Poor Clinical Outcomes M A R C H 2 4 , 2 0 1 5 : 1 1 0 7 – 1 5
1110DISCUSSION
The most important ﬁnding in this paper is that
among patients with complex CAD undergoing
revascularization with either PCI or CABG, those who
are smokers have a higher incidence of adverse out-
comes including MI than those who never smoked orstopped smoking. This ﬁnding is seen irrespective of
the speciﬁc revascularization strategy.
The SYNTAX trial enrolled patients with complex
CAD requiring coronary revascularization. It is note-
worthy that 1 in 5 patients with extensive coronary
disease were still smoking at the time of trial enroll-
ment. These data are consistent with other studies
showing that a sizeable proportion (10% to 30%) of
patients with established CAD continue to smoke
(18,22–24). The number of smokers was halved after
coronary revascularization, suggesting that most of
the patients took the smoking cessation advice at the
time of revascularization seriously (24). The time
of revascularization, therefore, presents a good op-
portunity to reinforce smoking cessation advice and
to offer practical help.
Smoking is a modiﬁable risk factor, and not all
current smokers remain smokers after a coronary
event or procedure. Conversely, patients may start
smoking again at any time during follow-up. Thus,
using baseline smoking status to predict long-term
outcomes is a potentially ﬂawed approach. We have,
therefore, used smoking status as a time-dependent
variable. Indeed, our results conﬁrm that this
approach, not unadjusted baseline smoking status, is
able to identify the link between smoking and poor
outcomes after revascularization. Another study
looking at the effect of smoking in patients under-
going CABG has suggested that smoking status at
baseline (pre-surgery) was not associated with
adverse outcomes but smoking status at follow-up
(post-surgery) predicted poor outcomes (13).
IMPACT OF SMOKING ON OUTCOMES: NO PARADOX
EXISTS. Smoking was associated with adverse out-
comes, especially recurrent MI in our study. This was
seen after adjusting for confounding variables or us-
ing smoking as a time-dependent covariate. Smoking
is a well-established risk factor for acute MI; quitting
reduces the risk of subsequent myocardial infarctions
(25). It has also been shown in multiple studies that a
ban on smoking substantially reduces the incidence
of MI, even at the population level (26–28). Adherence
to behavioral advice, including smoking cessation,
after an acute coronary syndrome is associated with a
substantially lower risk of recurrent cardiovascular
events (29). There was no signiﬁcant effect of smok-
ing on repeat revascularization, consistent with pre-
vious reports (18,30), although some studies have
reported opposing results (31). It is possible that drug-
eluting stents are associated with a lower incidence of
target lesion revascularization even in those who
continue to smoke (30). Our study did not show any
statistically signiﬁcant inﬂuence of smoking on
FIGURE 2 Kaplan-Meier Cumulative Events for Primary Endpoint and MACCE
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(A) The baseline smoking status (current smoker vs. ex-smoker vs. nonsmoker) appeared to have no impact on death/myocardial infarction (MI)/stroke (primary
endpoint) and major adverse cardiac and cerebrovascular events (MACCE) (deﬁned as a combination of death/MI/stroke and target lesion revascularization) at 5-year
follow-up. (B) Analyzing the data for those smoking or not smoking at baseline also yielded similar results. (C) However, using smoking status as a time-dependent
covariate at follow-up, smoking was associated with an increased risk of death/MI/stroke and MACCE at ﬁnal 5-year follow-up. The hazard ratio with 95% conﬁdence
interval was calculated for outcomes at different follow-up time points. The beneﬁcial effect of nonsmoking, although less pronounced within the short term, was
maintained throughout 5-year follow-up.
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FIGURE 3 Association of Smoking Status With Clinical Outcomes at 5 Years
1.17 (0.79, 1.73)
1.07 (0.58, 1.97)
1.25 (0.75, 2.09)
1.10 (0.65, 1.84)
1.03 (0.43, 2.47)
1.16 (0.61, 2.21)
1.86 (1.21, 2.86)
2.21 (1.06, 4.60)
1.72 (1.00, 2.95)
1.43 (0.66, 3.08)
1.29 (0.48, 3.43)
1.57 (0.46, 5.38)
1.14 (0.83, 1.56)
1.34 (0.79, 2.27)
1.06 (0.72, 1.58)
1.54 (0.87, 2.73)
1.40 (0.56, 3.49)
1.69 (0.81, 3.52)
1.38 (1.02, 1.86)
1.48 (0.96, 2.29)
1.29 (0.85, 1.95)
1.28 (1.01, 1.61)
1.33 (0.93, 1.91)
1.24 (0.91, 1.68)
Clinical endpoints Group
All-cause death Overall
CABG
PCI
Cardiac death Overall
CABG
PCI
MI Overall
CABG
PCI
Stroke Overall
CABG
PCI
All-cause revascularization Overall
CABG
PCI
ST or GO Overall
CABG
PCI
Death/MI/Stroke Overall
CABG
PCI
MACCE Overall
CABG
PCI
HR (95% CI) p-value Interactionp-value
0.675
0.836
0.256
0.903
0.549
0.721
0.488
0.611
0.447
0.833
0.396
0.727
0.948
0.649
0.005
0.034
0.049
0.359
0.613
0.475
0.416
0.282
0.758
0.138
0.467
0.164
0.035
0.075
0.227
0.041
0.117
0.178
0.1 0.2 0.5
Favors Smoking
51 2
Favors Not-smoking
10
This forest plot shows clinical outcomes according to smoking status (as a time-dependent covariate) in the overall SYNTAX (SYNergy Between
PCI With TAXUS and Cardiac Surgery) trial population and 2 revascularization strategies. A nonsigniﬁcant p value for interaction indicates that
the hazard ratio (HR) of smoking versus not smoking remained similar across the respective percutaneous coronary intervention (PCI) and
coronary artery bypass grafting (CABG) subgroups. CI ¼ conﬁdence interval; GO ¼ graft occlusion; ST ¼ stent thrombosis.
TABLE 3 Independent Predictors of Outcomes Using Smoking as
Time-Dependent Covariate
Variables HR 95% CI p Value
Death/MI/stroke
Smoking 1.799 1.273–2.543 0.001
PCI vs. CABG 1.292 1.015–1.645 0.038
Age per increase in 10 years 1.548 1.345–1.781 <0.001
COPD 1.523 1.071–2.168 0.019
PVD 1.849 1.344–2.543 <0.001
LVEF <30% 2.029 1.022–4.031 0.043
Amiodarone therapy on discharge 2.970 1.451–6.079 0.003
MACCE
Smoking 1.354 1.052–1.743 0.019
Zhang et al. J A C C V O L . 6 5 , N O . 1 1 , 2 0 1 5
SYNTAX, Smoking, and Poor Clinical Outcomes M A R C H 2 4 , 2 0 1 5 : 1 1 0 7 – 1 5
1112mortality despite a 17% higher relative risk of mor-
tality in smokers, possibly reﬂecting lack of adequate
power to demonstrate an effect on mortality. Other
studies with larger sample sizes have shown higher
mortality in smokers undergoing CABG or PCI (15,23).
It has also been shown that smokers demonstrate
less improvement in quality of life after coronary
revascularization (32). Therefore, it is prudent to
highlight that smoker’s paradox does not exist for
patients undergoing coronary revascularization and
that smoking cessation before such revascularization
is strongly advised to improve outcomes.TABLE 2 Adjusted Cumulative Effect of Smoking Status on MI
Follow-Up
(Months)
HR
(Smoking vs. Nonsmoking) 95% CI p Value
6 2.156 1.201–3.871 0.010
12 2.326 1.325–4.084 0.003
36 1.915 1.132–3.242 0.015
60 2.081 1.304–3.319 0.002
CI ¼ conﬁdence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction.
PCI vs. CABG 1.451 1.220–1.726 <0.001
Age per increase in 10 years 1.162 1.060–1.273 0.001
COPD 1.311 0.997–1.724 0.052
PVD 1.673 1.306–2.142 <0.001
Diabetes 1.324 1.102–1.589 0.003
LVEF <30% 1.853 1.084–3.167 0.024
SYNTAX score per point 1.009 1.001–1.017 0.027
BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; COPD ¼ chronic
obstructive pulmonary disease; LVEF ¼ left ventricular ejection fraction; MACCE ¼
major adverse cardiac and cerebrovascular event(s); PCI ¼ percutaneous coronary
intervention; PVD ¼ peripheral vascular disease; SYNTAX ¼ SYNergy Between PCI
With TAXUS and Cardiac Surgery; other abbreviations as in Table 2.
CENTRAL ILLUSTRATION Smoking Associated With Poor Clinical Outcomes: Adjusted Kaplan-Meier Cumulative Events for
Primary Endpoint and MACCE
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(A) After adjusting for confounding variables, baseline smoking status (current smoker vs. ex-smoker vs. nonsmoker) appeared to have no impact onmajor adverse cardiac
and cerebrovascular events (MACCE) (deﬁned as a combination of death/myocardial infarction [MI]/stroke and target lesion revascularization), but current smokers had
signiﬁcantly higher rate of death/MI/stroke (the primary endpoint) at 5-year follow-up. (B) Analyzing the data for those smoking or not smoking at baseline yielded
similar results. (C) Using smoking status as a time-dependent covariate at follow-up after adjusting baseline characteristics, nonsmoking signiﬁcantly lowered the risk of
death/MI/stroke and MACCE at ﬁnal 5-year follow-up. Hazard ratios with 95% conﬁdence intervals were calculated for outcomes at different follow-up time points.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Cigarette smoking is an established risk factor for
development of coronary artery disease, and studies
suggesting that smokers with coronary disease might
enjoy paradoxically better outcomes than nonsmokers
have not sufﬁciently considered baseline differences
in clinical risk factors or changes in smoking status
over time. After PCI or CABG, smokers with complex
coronary disease face a higher incidence of myocardial
infarction, and abstinence from smoking improves
outcomes.
COMPETENCY IN PATIENT CARE: All patients
undergoing PCI or CABG should be encouraged to
completely and permanently stop smoking.
TRANSLATIONAL OUTLOOK: Additional work is
needed to develop more effective and well-tolerated
methods to facilitate cessation and sustained absti-
nence from cigarette smoking.
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1114CLINICAL IMPLICATIONS. Smoking is associated
with poor outcomes after coronary revascularization
with PCI or CABG. This message needs to be dissem-
inated to patients, primary and secondary care phy-
sicians, and the general population. It is important
to inquire about smoking status at each clinical
encounter, and appropriate advice should be offered
to help patients stop smoking. Dedicated smoking
cessation programs may help patients achieve
smoking cessation (33). However, these patients
remain at risk of relapse. Patients who had bypass
surgery are more prone to return to smoking than
those who had an MI (34). Primary care and
community-based physicians and nurses may play an
important role improving smoking cessation rates.
STUDY STRENGTHS AND LIMITATIONS. The main
strength of our study is that smoking status was
checked at serial time points in this all-comers clin-
ical trial in patients with complex CAD. However, this
is a post-hoc analysis and has limitations inherent to
any such analysis. The smoking status presented here
is self-reported; there was no biochemical testing
(e.g., cotinine measurement) or cross validation of
smoking status. Number of cigarettes smoked by
current or ex-smokers was not recorded. However, it
could be argued that for cardiovascular outcomes,
including MI and stroke, smoking status is more
important than actual number of cigarettes smoked;
in the CADILLAC (Controlled Abciximab and Device
Investigation to Lower Late Angioplasty Complica-
tions) trial, 1-year mortality rates were similar among
those smoking less than a half pack per day, half to 1
pack per day, or more than 1 pack per day (19).
Smoking may have an acute effect on platelets and
endothelial function, leading to arterial thrombosis
and MI (35,36).
Another limitation is that the smoking status was
collected at pre-deﬁned intervals, and exact date of
change was not available. For example, if a patient was
smoking at 1 year and not smoking at 3 years, we
considered the patient a smoker at 1 year and ex-
smoker at 3 years, although the patient could have
stopped smoking at any time between 1 and 3 years.
However, we also performed a sensitivity analysis in a
completely opposite manner with the assumption that
patient stopped smoking just after the last visit (data
not shown), and the results remained unchanged.
Finally, the association does not confer a cause-
effect relationship. It is plausible that those who
continue to smoke may have additional lifestyle
risk factors (e.g., lack of exercise, unhealthy diet)
that could be contributing to the adverse outcomes
observed.CONCLUSIONS
Baseline smoking status may not provide adequate
information to predict the longer-term effects of
smoking on clinical outcomes due to changes in
smoking pattern during follow-up. Smoking is
associated with adverse clinical outcomes, espe-
cially MI, after revascularization for complex CAD.
Abstinence from smoking may improve the out-
comes achieved with coronary revascularization,
and all patients undergoing PCI or CABG should
be encouraged to stop smoking indeﬁnitely
before revascularization. Smoking cessation pro-
grams may help improve the beneﬁts achieved with
revascularization.
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